|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alternativeTo
|
Descovy (for some populations)
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AR03
|
|
gptkbp:brand
|
gptkb:emtricitabine/tenofovir_disoproxil_fumarate
|
|
gptkbp:contains
|
gptkb:tenofovir_disoproxil_fumarate
emtricitabine
|
|
gptkbp:contraindication
|
severe renal impairment
allergy to emtricitabine or tenofovir
|
|
gptkbp:cost
|
high in US, lower as generic
|
|
gptkbp:drugClass
|
antiretroviral therapy
protease inhibitor
|
|
gptkbp:effect
|
over 90% effective in preventing HIV with high adherence
|
|
gptkbp:firstApprovedForPrEP
|
2012
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
emtricitabine: ~10 hours
tenofovir: ~17 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Truvada (HIV PrEP)
|
|
gptkbp:indication
|
HIV prevention
HIV-1 infection
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
many countries worldwide
|
|
gptkbp:notEffectiveAgainst
|
other sexually transmitted infections
|
|
gptkbp:patentExpired
|
yes (in US, 2020)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:reduces
|
injection drug use transmission of HIV
sexual transmission of HIV
|
|
gptkbp:requiresHIVTestingBeforeStart
|
yes
|
|
gptkbp:requiresRegularMonitoring
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
renal impairment
decreased bone mineral density
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:takenOnceDaily
|
yes
|
|
gptkbp:usedFor
|
HIV treatment
HIV pre-exposure prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
5
|